21:19 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
23:31 , Dec 12, 2018 |  BC Extra  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cryptosporidium Cell culture and mouse studies identified two compounds that could help treat Cryptosporidium infections. Screening of 12,000 approved or investigational compounds in a C. parvum -infected human cell line identified two compounds, VB-201...
17:33 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Lilly's mirikizumab improves clinical remission in Phase II for ulcerative colitis

Eli Lilly and Co. (NYSE:LLY) reported in June that 200 mg IV mirikizumab (LY3074828) met the primary endpoint of improving clinical remission rate at week 12 vs. placebo in a Phase II trial to treat...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended...
22:08 , Jul 27, 2018 |  BC Extra  |  Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals Friday, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval...
22:53 , Jul 12, 2018 |  BC Extra  |  Politics & Policy

ICER panel votes against elagolix for endometriosis

An ICER panel showed little confidence in the clinical effectiveness of elagolix (ABT-620) from AbbVie Inc. (NYSE:ABBV) to treat endometriosis, voting Thursday that evidence is not adequate to support a net health benefit over other...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

Novartis AG (NYSE:NVS; SIX:NOVN) plans to begin the head-to-head Phase IIa ARROW trial to compare Cosentyx secukinumab to Tremfya guselkumab for 16 weeks in 40 patients with Stelara ustekinumab-resistant plaque psoriasis. The pharma expects to...